Results 41 to 50 of about 76,496 (274)

Treating HCV with ribavirin analogues and ribavirin-like molecules [PDF]

open access: yesJournal of Antimicrobial Chemotherapy, 2005
Nucleos(t)ide analogues have proven useful in the treatment of viral infections. Ribavirin is a nucleoside, guanosine analogue, whose mechanisms of action include inhibition of inosine monophosphate dehydrogenase (IMPDH), which is the key step in de novo guanine synthesis, a requirement for viral replication.
openaire   +3 more sources

Enhancement of Crystallization Process of the Organic Pharmaceutical Molecules through High Pressure

open access: yesCrystals, 2022
The enhancement of the crystallization process through high pressures was studied by using ribavirin (RVB) as a model compound. The effects of high pressure on crystallization thermodynamics, nucleation kinetics, and process yield were evaluated and ...
Yaoguang Feng   +5 more
doaj   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

open access: yes, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela   +4 more
core   +1 more source

Adverse Skin Reactions due to Ribavirin in Hepatitis C Combination Therapy with Pegylated Interferon-α2a

open access: yesCase Reports in Dermatology, 2013
The introduction of ribavirin to hepatitis C combination therapy with pegylated interferon (PEG-IFN)-α2a has improved sustained responses, but it has been accompanied by an increased incidence of cutaneous side effects. Most cases of drug eruption caused
Masahisa Shindo, Isamu Terai
doaj   +1 more source

Evaluation of Ribavirin–Poloxamer Microparticles for Improved Intranasal Absorption

open access: yesPharmaceutics, 2021
Ribavirin is a water-soluble antiviral compound which, owing to its inability to cross the blood–brain barrier, has limited effectiveness in treating viruses affecting the central nervous system.
Dipy M. Vasa   +4 more
doaj   +1 more source

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]

open access: yes, 2015
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A.   +2 more
core   +2 more sources

Middle East respiratory syndrome coronavirus: current situation and travel-associated concerns [PDF]

open access: yes, 2016
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A.   +2 more
core   +1 more source

Low-Dose Ribavirin Treatments Attenuate Neuroinflammatory Activation of BV-2 Cells by Interfering with Inducible Nitric Oxide Synthase

open access: yesAnalytical Cellular Pathology, 2015
Microglia play a key role in defending central nervous system from various internal and external threats. However, their excessive and/or chronic activation is associated with deleterious effects in a variety of neurodegenerative diseases. Previously, we
Iva Bozic   +8 more
doaj   +1 more source

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. [PDF]

open access: yesPLoS ONE, 2016
BACKGROUND:Ribavirin blood levels vary considerably between patients with standard weight-based dosing. Their impact on sustained virological response (SVR) with pegylated interferon and ribavirin is controversial, but has mostly been studied before the ...
Thomas Kuntzen   +5 more
doaj   +1 more source

Liver transplantation for viral hepatitis in 2015 [PDF]

open access: yes, 2016
Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy